ACRV
Acrivon Therapeutics, Inc. Common StockNASDAQHealthcare$1.52+4.11%ClosedMarket Cap: $48.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.54
P/S
0.00
EV/EBITDA
-0.13
DCF Value
$0.95
FCF Yield
-131.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.2%
ROA
-60.1%
ROIC
-73.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-20.1M | $-19.0M | $-0.49 | — |
| FY 2025 | $0.00 | -Infinity% | $-84.1M | $-77.9M | $-2.02 | — |
| Q3 2025 | $0.00 | -Infinity% | $-19.7M | $-18.2M | $-0.47 | — |
| Q2 2025 | $0.00 | -Infinity% | $-22.6M | $-21.0M | $-0.55 | — |
| Q1 2025 | $0.00 | -Infinity% | $-21.7M | $-19.7M | $-0.51 | — |
| Q4 2024 | $0.00 | -Infinity% | $-25.0M | $-22.8M | $-0.60 | — |
| FY 2024 | $0.00 | -Infinity% | $-89.2M | $-80.6M | $-2.10 | — |
| Q3 2024 | $0.00 | NaN% | $-25.1M | $-22.4M | $-0.59 | — |
| Q2 2024 | $0.00 | NaN% | $-21.4M | $-18.8M | $-0.52 | — |
| Q1 2024 | $0.00 | -Infinity% | $-17.7M | $-16.5M | $-0.73 | — |
| Q4 2023 | $0.00 | -Infinity% | $-21.1M | $-19.3M | $-0.86 | — |
| FY 2023 | $0.00 | -Infinity% | $-67.2M | $-60.4M | $-2.74 | — |